Prognostic and predictive markers in pancreatic adenocarcinoma
2016 (English)In: Digestive and Liver Disease, ISSN 1590-8658, E-ISSN 1878-3562, Vol. 48, no 3, 223-230 p.Article, review/survey (Refereed) PublishedText
Pancreatic ductal adenocarcinoma is characterized by a poor prognosis and a low median survival, despite improvements observed for many other solid tumours. Intensive research efforts have been undertaken during the last decades to discover new prognostic and treatment predictive biomarkers for pancreatic ductal adenocarcinoma. The mainstay of medical treatment for the disease has been the well-tolerated nucleoside analogue, gemcitabine. The only targeted agent currently used in pancreatic ductal adenocarcinoma patients is the epithelial growth factor receptor inhibitor erlotinib in combination with gemcitabine. Recently, treatment regimens such as a combination of fluorouracilleucovorin-irinotecan-oxaliplatin (FOLFIRINOX) and the combination of nab-paclitaxel with gemcitabine have been introduced for metastatic pancreatic ductal adenocarcinoma. Although these treatment regimens significantly improve survival of patients, there are no good predictive biomarkers available that can be used to identify who would benefit most from them. Therefore, the search for predictive biomarkers that would facilitate personalization of chemotherapy is highly relevant.
Place, publisher, year, edition, pages
2016. Vol. 48, no 3, 223-230 p.
Chemotherapy, Metastatic pancreatic cancer, Predictive marker, Prognostic marker
Cancer and Oncology
IdentifiersURN: urn:nbn:se:umu:diva-117805DOI: 10.1016/j.dld.2015.11.001ISI: 000369840400002OAI: oai:DiVA.org:umu-117805DiVA: diva2:918426